DelveInsight’s, “Follicular Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Follicular Lymphoma Pipeline Report

• DelveInsight’s Follicular Lymphoma Pipeline analysis depicts a robust space with 50+ Follicular Lymphoma companies working to develop 50+ pipeline treatment therapies.
• The leading companies working in the Follicular Lymphoma Market include Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
• Promising Follicular Lymphoma Pipeline Therapies in the various stages of development include DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
• December 2023: AbbVie announced a study of Phase 2 clinical trials for Epcoritamab, Rituximab and Lenalidomide. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1).
• On August 2023, AbbVie announced a study of phase 3 clinical trials for Epcoritamab, Rituximab, and Lenalidomide. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
• On August 2023, Celgene announced a study of phase 3 clinical trias for Rituximab and Lenalidomide. The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

 

Request a sample and discover the recent advances in Follicular Lymphoma Treatment Drugs @ Follicular Lymphoma Pipeline Outlook Report

 

In the Follicular Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Follicular Lymphoma Overview

Follicular lymphoma is a form of cancer. It is a type of non-Hodgkin lymphoma (NHL), which is a group of related cancers that affect the lymphatic system (lymphomas). The lymphatic system functions as part of the immune system and helps to protect the body against infection and disease. It consists of a network of tubular channels (lymph vessels) that drain a thin watery fluid known as lymph from different areas of the body into the bloodstream.

 

Find out more about Follicular Lymphoma Therapeutics Assessment @ Follicular Lymphoma Preclinical and Discovery Stage Products

 

Follicular Lymphoma Emerging Drugs Profile

• Tafasitamab: Incyte Corporation
• Epcoritamab: Genmab A/S
• Zanubrutinib – BeiGene
• Pembrolizumab: Merck & Co.

 

Follicular Lymphoma Pipeline Therapeutics Assessment

There are approx. 50+ Follicular Lymphoma companies which are developing the Follicular Lymphoma therapies. The Follicular Lymphoma companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III.

 

DelveInsight’s Follicular Lymphoma pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Follicular Lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging Follicular Lymphoma Pipeline Therapies @ Follicular Lymphoma Clinical Trials Assessment

 

Scope of the Follicular Lymphoma Pipeline Report

• Coverage- Global
• Follicular Lymphoma Companies- Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
• Follicular Lymphoma Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for new drugs for Follicular Lymphoma Treatment, Visit @ Follicular Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Follicular Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Follicular Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Zanubrutinib – BeiGene
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pembrolizumab: Merck & Co.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Follicular Lymphoma Key Companies
21. Follicular Lymphoma Key Products
22. Follicular Lymphoma- Unmet Needs
23. Follicular Lymphoma- Market Drivers and Barriers
24. Follicular Lymphoma- Future Perspectives and Conclusion
25. Follicular Lymphoma Analyst Views
26. Follicular Lymphoma Key Companies
27. Appendix

 

For further information on the Follicular Lymphoma Pipeline therapeutics, reach out to Follicular Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market